Want to see BNBX full AI Analyst Report?
Top Page
BNB Plus
(OTC:BNBX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.09
▼(-27.69% Downside)
Action:Reiterated
Date:10/17/26
The score is primarily constrained by very weak financial performance—extreme losses and significant cash burn despite improved revenue—followed by bearish technical signals with price below all key moving averages. Valuation offers limited support due to negative earnings, while corporate events are mixed with both a strategic pivot and restructuring/leadership-change risks.
Positive Factors
Revenue rebound
The sharp TTM revenue rebound indicates that the company has demonstrated some ability to expand its top line. If this growth can be sustained and converted into healthier margins, it could improve operating leverage, support reinvestment, and strengthen the business over the next several quarters.
Negative Factors
Severe unprofitability
The revenue rebound has not translated into earnings power: gross profitability remains low and operating and net losses are exceptionally large relative to sales. This indicates an outsized cost structure, making durable profitability dependent on substantial margin improvement or major operating changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp TTM revenue rebound indicates that the company has demonstrated some ability to expand its top line. If this growth can be sustained and converted into healthier margins, it could improve operating leverage, support reinvestment, and strengthen the business over the next several quarters.
Read all positive factors
BNB Plus (BNBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$613.06K
Dividend YieldN/A
Average Volume (3M)21.73K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth-27.39%
EPS Growth99.29%
CountryUS
Employees26
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,197,223
10 Day Avg. Volume23,026
30 Day Avg. Volume21,733
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap4.31
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit2.91
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BNB Plus Business Overview & Revenue Model
Company Description
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)....
BNB Plus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 2.14M | 3.43M | 13.37M | 18.17M | 9.03M |
| Gross Profit | 910.30K | 838.91K | 1.02M | 5.53M | 5.05M | 4.93M |
| EBITDA | -34.70M | -15.26M | -13.33M | -9.59M | -12.68M | -11.68M |
| Net Income | -34.48M | -15.16M | -6.99M | -9.95M | -8.38M | -16.03M |
Balance Sheet | ||||||
| Total Assets | 13.63M | 4.44M | 12.79M | 13.65M | 22.27M | 14.42M |
| Cash, Cash Equivalents and Short-Term Investments | 949.09K | 1.67M | 6.43M | 7.15M | 15.22M | 6.55M |
| Total Debt | 0.00 | 193.25K | 739.16K | 1.24M | 0.00 | 0.00 |
| Total Liabilities | 1.50M | 2.50M | 3.82M | 8.78M | 9.36M | 3.30M |
| Stockholders Equity | 12.51M | 2.30M | 9.14M | 4.95M | 12.91M | 11.11M |
Cash Flow | ||||||
| Free Cash Flow | -13.80M | -12.83M | -14.12M | -6.30M | -9.47M | -15.94M |
| Operating Cash Flow | -13.79M | -12.52M | -13.71M | -6.22M | -8.98M | -13.39M |
| Investing Cash Flow | -2.96M | -292.12K | -407.90K | -1.10M | -489.55K | -2.55M |
| Financing Cash Flow | 9.96M | 8.05M | 13.40M | 0.00 | 18.13M | 14.70M |
BNB Plus Technical Analysis
Negative
0.13
Price Trends
0.13
Negative
0.20
Negative
0.49
Negative
Market Momentum
-0.01
Positive
38.49
Neutral
5.65
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.13, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.49 is Neutral, neither overbought nor oversold. The STOCH value of 5.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.
BNB Plus Risk Analysis
BNB Plus disclosed 41 risk factors in its most recent earnings report. BNB Plus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BNB Plus Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
51 Neutral | $7.44M | -0.78 | -224.80% | ― | ― | 98.17% | |
44 Neutral | $5.70M | -0.18 | -170.36% | ― | 38.09% | 54.22% | |
42 Neutral | $2.20M | -0.02 | -524.37% | ― | -92.11% | 86.78% | |
41 Neutral | $613.06K | >-0.01 | -337.10% | ― | -27.39% | 99.29% |
* Financial Sector Average
BNBX
BNB Plus
0.10
-3.53
-97.30%
NDRA
ENDRA Life Sciences
4.96
-0.05
-0.98%
INBS
Intelligent Bio Solutions
1.72
-7.79
-81.91%
ISPC
iSpecimen
0.87
-31.24
-97.28%
BGLC
BioNexus Gene Lab Corp
1.13
-3.99
-77.93%
BNB Plus Corporate Events
Business Operations and Strategy
BNB Plus pivots to institutional blockchain and AI
Positive
Oct 2, 2026
On October 2, 2026, BNB Plus Corp. announced a strategic shift from a passive digital asset treasury focused on the BNB Chain to an operating model building infrastructure for financial institutions and enterprises to adopt blockchain and agentic ...
Business Operations and StrategyRegulatory Filings and Compliance
BNB Plus Amends Registration Rights Agreement for Flexibility
Neutral
Oct 1, 2026
BNB Plus is party to a Registration Rights Agreement governing how holders of its private-offering securities can obtain SEC registration for resale. The agreement covers “Registrable Securities” held by purchasers owning a majority in...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
BNB Plus Reshapes Board With New Investor-Linked Directors
Neutral
Sep 3, 2026
On September 2, 2026, BNB Plus Corp. announced that directors Robert B. Catell, Joseph D. Ceccoli and Dr. Yacov Shamash resigned from the board effective September 3, 2026, with the company stating the departures were not due to disagreements over...
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsPrivate Placements and FinancingRegulatory Filings and Compliance
BNB Plus Restructures Agreements and Leadership with Cypress
Negative
Jul 29, 2026
On July 23, 2026, BNB Plus and its Cypress-affiliated partners entered into a Settlement Agreement that terminated prior strategic digital asset management, advisory and consulting contracts dating from 2025, in exchange for $1 million in cash ove...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.